Advate Purple Book BLA 125063

BLA number
125063
Proprietary names
Advate
Proper names
Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method
Applicant
Takeda Pharmaceuticals U.S.A., Inc.
Center
CBER
First observed release
2020-08-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001AdvateAntihemophilic Factor (Recombinant), Plasma/Albumin Free Method351(a)1500IUFor InjectionIntravenousSingle-Dose VialRxLicensed2003-07-25
002AdvateAntihemophilic Factor (Recombinant), Plasma/Albumin Free Method351(a)500IUFor InjectionIntravenousSingle-Dose VialRxLicensed2003-07-25
003AdvateAntihemophilic Factor (Recombinant), Plasma/Albumin Free Method351(a)250IUFor InjectionIntravenousSingle-Dose VialRxLicensed2003-07-25
004AdvateAntihemophilic Factor (Recombinant), Plasma/Albumin Free Method351(a)1000IUFor InjectionIntravenousSingle-Dose VialRxLicensed2003-07-25
005AdvateAntihemophilic Factor (Recombinant), Plasma/Albumin Free Method351(a)2000IUFor InjectionIntravenousSingle-Dose VialRxLicensed2006-04-12
006AdvateAntihemophilic Factor (Recombinant), Plasma/Albumin Free Method351(a)3000IUFor InjectionIntravenousSingle-Dose VialRxLicensed2007-07-03
007AdvateAntihemophilic Factor (Recombinant), Plasma/Albumin Free Method351(a)4,000IUFor InjectionIntravenousSingle-Dose VialRxLicensed2012-07-12

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2023-05-01U001Advate351(a)RxTakeda Pharmaceuticals U.S.A., Inc.
2023-05-01U002Advate351(a)RxTakeda Pharmaceuticals U.S.A., Inc.
2023-05-01U003Advate351(a)RxTakeda Pharmaceuticals U.S.A., Inc.
2023-05-01U004Advate351(a)RxTakeda Pharmaceuticals U.S.A., Inc.
2023-05-01U005Advate351(a)RxTakeda Pharmaceuticals U.S.A., Inc.
2023-05-01U006Advate351(a)RxTakeda Pharmaceuticals U.S.A., Inc.
2023-05-01U007Advate351(a)RxTakeda Pharmaceuticals U.S.A., Inc.
2021-05-01U001Advate351(a)RxBaxalta US Inc.
2021-05-01U002Advate351(a)RxBaxalta US Inc.
2021-05-01U003Advate351(a)RxBaxalta US Inc.
2021-05-01U004Advate351(a)RxBaxalta US Inc.
2021-05-01U005Advate351(a)RxBaxalta US Inc.
2021-05-01U006Advate351(a)RxBaxalta US Inc.
2021-05-01U007Advate351(a)RxBaxalta US Inc.
2020-08-01R001Advate351(a)RxBaxalta US Inc.
2020-08-01R002Advate351(a)RxBaxalta US Inc.
2020-08-01R003Advate351(a)RxBaxalta US Inc.
2020-08-01R004Advate351(a)RxBaxalta US Inc.
2020-08-01R005Advate351(a)RxBaxalta US Inc.
2020-08-01R006Advate351(a)RxBaxalta US Inc.
2020-08-01R007Advate351(a)RxBaxalta US Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-08-01001Advate351(a)RxLicensed2003-07-25
2020-08-01002Advate351(a)RxLicensed2003-07-25
2020-08-01003Advate351(a)RxLicensed2003-07-25
2020-08-01004Advate351(a)RxLicensed2003-07-25
2020-08-01005Advate351(a)RxLicensed2006-04-12
2020-08-01006Advate351(a)RxLicensed2007-07-03
2020-08-01007Advate351(a)RxLicensed2012-07-12